India has a high incidence of pre-diabetes with almost 5%–10% cases advancing to diabetes. Glucagon-like peptide-1 receptor agonists have been shown to efficaciously reduce this progression and promote regression to normoglycemia. However, their effectiveness in real-world settings remains to be studied. To overcome this, researchers tested the clinical effectiveness of dulaglutide monotherapy in obese patients with prediabetes, in a first-of-its-kind study.
The study involved a retrospective analysis of 11 adults with obesity and prediabetes, receiving dulaglutide. These patients were analyzed for changes in glycemic parameters, body weight, and adverse effects after receiving dulaglutide. A t-test was used to analyze the outcomes. When followed up for six months, dulaglutide led to a significant reduction in the fasting blood glucose (FBG) levels (MR, 28 mg/dL; [95% CI: 19.94-36.06];…
